BioSpace News Archive

Thursday, October 24, 2019, at 7:30 a.m. Central Time.

Vanguard Supports First-of-Its-Kind Project Integrating Home Visiting Nurses into Pediatric Primary Care Setting

Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study

Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated -- without opioids -- announced new results from its Phase I study for NTM-001 at PAINWeek 2019.

Altasciences is pleased to announce the addition of Dr. Lynne LeSauteur, PhD, to their bioanalytical management team, responsible for the Bioanalytical Services department in the U.S.A. and the Ligand Binding team in Canada.

CAMBRIDGE, Mass., Sept. 4, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the initiation of two clinical trials for IPI-549, a first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma.

Beam Therapeutics announced the appointment of financial industry veteran, Terry-Ann Burrell, as chief financial officer.

Devonian Health Group Inc. announced that it has formed a Clinical Dermatology Advisory Board comprised of Canadian Key Opinion Leaders.

Research Foundation to Cure AIDS (RFTCA) has obtained a worldwide license to biotechnology known as Chromovert® Technology, to research, develop and commercialize a cure for HIV/AIDS.

Jeffery Bullard, MD, a trailblazing physician and health care entrepreneur and innovator, has been named the new Chief Medical Officer for the Catalyst Health Network.